SEK 3.36
(-7.69%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 223 Thousand SEK | 0.0% |
2022 | - SEK | -100.0% |
2021 | 100 Thousand SEK | -50.0% |
2020 | 200 Thousand SEK | -66.67% |
2019 | 600 Thousand SEK | -40.0% |
2018 | 1 Million SEK | -28.57% |
2017 | 1.4 Million SEK | 0.0% |
2016 | - SEK | 0.0% |
2015 | - SEK | 0.0% |
2014 | - SEK | 0.0% |
2013 | - SEK | -100.0% |
2012 | 73.5 Thousand SEK | -49.94% |
2011 | 146.83 Thousand SEK | 0.0% |
2010 | - SEK | 0.0% |
2009 | - SEK | 0.0% |
2008 | - SEK | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 223 Thousand SEK | -100.0% |
2024 Q3 | - SEK | 0.0% |
2024 Q2 | 223 Thousand SEK | 0.0% |
2023 Q1 | - SEK | 0.0% |
2023 Q4 | 223 Thousand SEK | -5.11% |
2023 FY | 223 Thousand SEK | 0.0% |
2023 Q3 | 235 Thousand SEK | 0.0% |
2023 Q2 | - SEK | 0.0% |
2022 Q1 | 50 Thousand SEK | -50.0% |
2022 Q4 | - SEK | 0.0% |
2022 Q3 | - SEK | 0.0% |
2022 FY | - SEK | -100.0% |
2022 Q2 | - SEK | -100.0% |
2021 Q1 | 200 Thousand SEK | 0.0% |
2021 Q3 | 200 Thousand SEK | 0.0% |
2021 Q4 | 100 Thousand SEK | -50.0% |
2021 FY | 100 Thousand SEK | -50.0% |
2021 Q2 | 200 Thousand SEK | 0.0% |
2020 Q3 | 600 Thousand SEK | 0.0% |
2020 FY | 200 Thousand SEK | -66.67% |
2020 Q1 | 600 Thousand SEK | 0.0% |
2020 Q2 | 600 Thousand SEK | 0.0% |
2020 Q4 | 200 Thousand SEK | -66.67% |
2019 FY | 600 Thousand SEK | -40.0% |
2019 Q2 | 21 Million SEK | 2000.0% |
2019 Q3 | 21 Million SEK | 0.0% |
2019 Q4 | 600 Thousand SEK | -97.14% |
2019 Q1 | 1 Million SEK | 0.0% |
2018 Q1 | 1.4 Million SEK | 0.0% |
2018 Q4 | 1 Million SEK | -28.57% |
2018 Q3 | 1.4 Million SEK | 0.0% |
2018 Q2 | 1.4 Million SEK | 0.0% |
2018 FY | 1 Million SEK | -28.57% |
2017 Q2 | 2 Million SEK | 0.0% |
2017 Q1 | - SEK | 0.0% |
2017 FY | 1.4 Million SEK | 0.0% |
2017 Q4 | 1.4 Million SEK | -26.32% |
2017 Q3 | 1.9 Million SEK | -5.0% |
2016 FY | - SEK | 0.0% |
2016 Q4 | - SEK | 0.0% |
2016 Q1 | - SEK | 0.0% |
2016 Q3 | - SEK | 0.0% |
2016 Q2 | - SEK | 0.0% |
2015 Q1 | - SEK | 0.0% |
2015 FY | - SEK | 0.0% |
2015 Q4 | - SEK | 0.0% |
2015 Q3 | - SEK | 0.0% |
2015 Q2 | - SEK | 0.0% |
2014 Q2 | - SEK | 0.0% |
2014 Q4 | - SEK | 0.0% |
2014 Q3 | - SEK | 0.0% |
2014 FY | - SEK | 0.0% |
2014 Q1 | - SEK | 0.0% |
2013 Q3 | 73.5 Thousand SEK | 0.0% |
2013 Q4 | - SEK | -100.0% |
2013 FY | - SEK | -100.0% |
2013 Q1 | 73.5 Thousand SEK | 0.0% |
2013 Q2 | 73.5 Thousand SEK | 0.0% |
2012 FY | 73.5 Thousand SEK | -49.94% |
2012 Q4 | 73.5 Thousand SEK | -49.37% |
2012 Q2 | - SEK | 0.0% |
2012 Q3 | 145.16 Thousand SEK | 0.0% |
2012 Q1 | - SEK | -100.0% |
2011 Q3 | - SEK | 0.0% |
2011 Q4 | 146.83 Thousand SEK | 0.0% |
2011 Q1 | - SEK | 0.0% |
2011 FY | 146.83 Thousand SEK | 0.0% |
2011 Q2 | - SEK | 0.0% |
2010 Q4 | - SEK | 0.0% |
2010 Q1 | - SEK | 0.0% |
2010 Q2 | - SEK | 0.0% |
2010 FY | - SEK | 0.0% |
2010 Q3 | - SEK | 0.0% |
2009 Q3 | - SEK | 0.0% |
2009 FY | - SEK | 0.0% |
2009 Q4 | - SEK | 0.0% |
2009 Q2 | - SEK | 0.0% |
2008 Q4 | - SEK | 0.0% |
2008 FY | - SEK | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Acarix AB (publ) | - SEK | -Infinity% |
ADDvise Group AB (publ) | 1.45 Billion SEK | 99.985% |
ADDvise Group AB (publ) | 1.45 Billion SEK | 99.985% |
Arcoma AB | 1.92 Million SEK | 88.428% |
Bactiguard Holding AB (publ) | 42.3 Million SEK | 99.473% |
BICO Group AB (publ) | 1.75 Billion SEK | 99.987% |
Boule Diagnostics AB (publ) | 57.7 Million SEK | 99.614% |
CellaVision AB (publ) | 28.66 Million SEK | 99.222% |
Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
C-Rad AB (publ) | 1.75 Million SEK | 87.279% |
Duearity AB (publ) | 2.94 Million SEK | 92.415% |
Dignitana AB (publ) | 6.07 Million SEK | 96.33% |
Episurf Medical AB (publ) | 2.3 Million SEK | 90.304% |
Getinge AB (publ) | 3.9 Billion SEK | 99.994% |
Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 96.49% |
Iconovo AB (publ) | 4.9 Million SEK | 95.455% |
Integrum AB (publ) | 4.84 Million SEK | 95.397% |
Luxbright AB (publ) | 206.02 Thousand SEK | -8.24% |
Mentice AB (publ) | 2.14 Million SEK | 89.599% |
OssDsign AB (publ) | 214 Thousand SEK | -4.206% |
Paxman AB (publ) | 2.53 Million SEK | 91.193% |
Promimic AB (publ) | - SEK | -Infinity% |
Qlife Holding AB (publ) | 3 Million SEK | 92.577% |
SciBase Holding AB (publ) | 4.17 Million SEK | 94.664% |
ScandiDos AB (publ) | - SEK | -Infinity% |
Sectra AB (publ) | 19.2 Million SEK | 98.839% |
Sedana Medical AB (publ) | 1.01 Million SEK | 77.964% |
Senzime AB (publ) | 8.57 Million SEK | 97.4% |
SpectraCure AB (publ) | 4.39 Million SEK | 94.928% |
Stille AB | 38.06 Million SEK | 99.414% |
Vitrolife AB (publ) | 1.87 Billion SEK | 99.988% |
Xvivo Perfusion AB (publ) | 21.16 Million SEK | 98.947% |